FDA officials questioned why the generic industry feels its pharmacovigilance information is sufficient to suggest labeling changes in other countries, but inadequate for the same task in the U.S., which would be required under the proposed generic labeling reg.
A number of generic company representatives said during a March 27 public meeting on the controversial proposed rule that it...